SCHEMBL352306

SCHEMBL352306

CCc1cc(C(=O)O)cs1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 4/20 1.00
RAB9A P51151 6/20 0.58
TP53 P04637 2/20 0.58
USP2 O75604 1/20 0.53
GAA P10253 5/20 0.51
LMNA P02545 5/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
SMN1; SMN2 Q16637 6/20 0.47
MAPT P10636 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 2/20 0.45
NPC1 O15118 4/20 0.43
ALDH1A1 P00352 5/20 0.43
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL28127314 0.98 DAO (0.96) DAORAB9ATP53USP2GAA
SCHEMBL2140946 0.84 DAO (0.72) DAORAB9ATP53USP2GAA
SCHEMBL10163846 0.82 DAO (0.69) DAORAB9ATP53USP2GAA
SCHEMBL1701349 0.82 DAO (0.69) DAORAB9ATP53USP2GAA
SCHEMBL11398245 0.81 DAO (0.68) DAORAB9ATP53GAALMNA
SCHEMBL4171556 0.81 DAO (0.68) DAORAB9ATP53USP2GAA
SCHEMBL30295668 0.80 DAO (0.67) DAORAB9ATP53USP2GAA
SCHEMBL2913260 0.80 DAO (0.66) DAORAB9ATP53GAALMNA
SCHEMBL3635029 0.79 DAO (0.66) DAORAB9ATP53USP2GAA
SCHEMBL13614249 0.79 DAO (0.66) DAORAB9ATP53USP2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP claimed
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US claimed
CN-101516834-A Isoserine derivatives for use as coagulation factor ixa inhibitors SANOFI AVENTIS (FR) 2009-08-26 CN claimed
EP-4737449-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2026-05-06 EP disclosed
US-20250066369-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES NodThera Limited (GB) 2025-02-27 US disclosed
WO-2025002177-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF 长春金赛药业有限责任公司 2025-01-02 WO disclosed
EP-4460505-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES Nodthera Limited (GB) 2024-11-13 EP disclosed
CN-118922421-A Bicyclic phthalazin-1 (2H) -one derivatives and related uses 诺瑟拉有限公司 2024-11-08 CN disclosed
WO-2023133271-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES NodThera Limited (GB) 2023-07-13 WO disclosed
WO-2023133271-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES NodThera Limited (GB) 2023-07-13 WO disclosed
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20070155739-A1 Substituted bis-amide metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed
US-20070155739-A1 Substituted bis-amide metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed
US-20070155739-A1 Substituted bis-amide metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed
US-20060293345-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2006-12-28 US disclosed
WO-2006128184-A2 PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS ALANTOS-PHARMACEUTICALS, INC. (US) 2006-11-30 WO disclosed
WO-2006083454-A1 MULTICYCLIC BIS-AMIDE MMP INHIBITORS ALANTOS PHARMACEUTICALS, INC. (US) 2006-08-10 WO disclosed
US-20060173183-A1 Multicyclic bis-amide MMP inhibitors ALANTOS PHARMACEUTICALS, INC., 2006-08-03 US disclosed
CN-1359423-A Herbicide resistant plants HINZENTA CO LTD (GB) 2002-07-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066369-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES IL1B, NLRP3, IL1A DAO 4052/4885RAB9A 2808/4885TP53 292/4885
US-20060293345-A1 Heterobicyclic metalloprotease inhibitors MMP13, MMP3, MMP10 DAO 762/4885RAB9A 1332/4885TP53 3384/4885
US-20060173183-A1 Multicyclic bis-amide MMP inhibitors MMP13, MMP3, MMP11 DAO 337/4885RAB9A 934/4885TP53 1942/4885
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS TFPI, F2, F9 DAO 286/4885RAB9A 1502/4885TP53 4568/4885
US-20070155739-A1 Substituted bis-amide metalloprotease inhibitors MMP13, MMP9, ADAMTS13 DAO 189/4885RAB9A 1295/4885TP53 1729/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 DAO 698/4885RAB9A 1239/4885TP53 3627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.